Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 31;13(1):91.
doi: 10.1038/s41408-023-00859-x.

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

I Vaxman  1   2   3 , S K Kumar  1 , F Buadi  1 , M Q Lacy  1 , D Dingli  1 , S Hayman  1 , T Kourelis  1 , R Warsame  1 , Y Hwa  1 , A Fonder  1 , M Hobbs  1 , E Muchtar  1 , N Leung  1 , P Kapoor  1 , R Go  1 , Y Lin  1 , W Gonsalves  1 , M Siddiqui  1 , R A Kyle  1 , S V Rajkumar  1 , M A Gertz  1 , A Dispenzieri  4
Affiliations

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

I Vaxman et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Response and survival.
a Clinical, hematological, PET, and VEGF responses in POEMS patients treated with daratumumab-based therapies and carfilzomib-based therapies. b Time to next treatment.
See this image and copyright information in PMC

References

    1. Kuwabara S, Dispenzieri A, Arimura K, Misawa S, Nakaseko C. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012;2012:Cd006828. - PMC - PubMed
    1. Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, et al. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia. 2016;30:1079–85. doi: 10.1038/leu.2015.344. - DOI - PubMed
    1. Jurczyszyn A, Castillo JJ, Olszewska-Szopa M, Kumar L, Thibaud S, Richter J. POEMS syndrome: real world experience in diagnosis and systemic therapy-108 patients multicenter analysis. Clin Lymphoma Myeloma Leuk. 2022;22:297–304. doi: 10.1016/j.clml.2021.10.007. - DOI - PubMed
    1. Pramanik R, Sharma A, Sharma A, Gogia A, Sahoo RK, Malik PS, et al. POEMS Syndrome: Indian experience from a tertiary-care institute. Clin Lymphoma Myeloma Leuk. 2019;19:e536–e544. doi: 10.1016/j.clml.2019.05.018. - DOI - PubMed
    1. Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23:65–76. doi: 10.1016/S1470-2045(21)00579-9. - DOI - PubMed

Publication types

MeSH terms